Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BSGMNASDAQ:PETVNASDAQ:PSTVNASDAQ:QNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSGMBioSig Technologies$1.22+18.4%$0.70$0.20▼$2.57$29.59M0.79223,790 shs568,798 shsPETVPetVivo$0.60-4.5%$0.55$0.29▼$0.98$14.56M1.8520,614 shs26,517 shsPSTVPlus Therapeutics$0.65-9.6%$0.88$0.24▼$2.67$11.05M0.684.25 million shs1.41 million shsQNRXQuoin Pharmaceuticals$6.85+1.2%$8.62$5.01▼$54.95$4.03M1.8994,235 shs18,937 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSGMBioSig Technologies+11.94%+60.94%+71.32%+25.12%-37.95%PETVPetVivo+8.48%+21.26%+4.92%-18.13%-24.10%PSTVPlus Therapeutics-6.48%-26.86%-24.28%-40.06%-58.67%QNRXQuoin Pharmaceuticals+2.89%+3.20%-13.61%-33.05%-72.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSGMBioSig Technologies2.2669 of 5 stars3.50.00.00.03.60.80.6PETVPetVivoN/AN/AN/AN/AN/AN/AN/AN/APSTVPlus Therapeutics2.2339 of 5 stars3.54.00.00.02.10.00.6QNRXQuoin Pharmaceuticals0.6623 of 5 stars0.03.00.00.03.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSGMBioSig Technologies 3.00Buy$2.50104.92% UpsidePETVPetVivo 0.00N/AN/AN/APSTVPlus Therapeutics 3.00Buy$11.501,668.96% UpsideQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QNRX, PSTV, PETV, and BSGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025BSGMBioSig TechnologiesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.75 ➝ $2.504/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.003/28/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/28/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.503/17/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$9.00 ➝ $9.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSGMBioSig Technologies$40K739.69N/AN/A($0.33) per share-3.70PETVPetVivo$1.05M13.91N/AN/A($0.03) per share-20.03PSTVPlus Therapeutics$4.91M2.25N/AN/A($0.30) per share-2.17QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$5.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSGMBioSig Technologies-$29.04MN/A0.00N/AN/A-44,832.50%N/A-776.49%5/19/2025 (Estimated)PETVPetVivo-$10.95M-$0.45N/A∞N/A-902.82%-4,813.07%-281.78%6/26/2025 (Estimated)PSTVPlus Therapeutics-$13.32M-$2.50N/AN/AN/A-225.07%N/A-154.56%5/13/2025 (Estimated)QNRXQuoin Pharmaceuticals-$8.69M-$81.12N/AN/AN/AN/A-125.60%-64.77%5/8/2025 (Estimated)Latest QNRX, PSTV, PETV, and BSGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025PSTVPlus Therapeutics-$0.24N/AN/AN/A$1.11 millionN/A5/19/2025N/ABSGMBioSig Technologies-$0.18N/AN/AN/AN/AN/A5/8/2025Q1 2025QNRXQuoin Pharmaceuticals-$0.11N/AN/AN/AN/AN/A3/27/2025Q4 2024PSTVPlus Therapeutics-$0.51-$0.67-$0.16-$0.67$1.19 million$1.80 million3/13/2025Q4 2024QNRXQuoin Pharmaceuticals-$17.50-$12.25+$5.25-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSGMBioSig TechnologiesN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSGMBioSig TechnologiesN/A0.500.50PETVPetVivo0.020.420.47PSTVPlus TherapeuticsN/A0.440.44QNRXQuoin PharmaceuticalsN/A3.023.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSGMBioSig Technologies7.16%PETVPetVivo24.55%PSTVPlus Therapeutics3.28%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipBSGMBioSig Technologies17.03%PETVPetVivo10.84%PSTVPlus Therapeutics5.49%QNRXQuoin Pharmaceuticals3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSGMBioSig Technologies5024.25 million14.30 millionNo DataPETVPetVivo2024.22 million19.06 millionNot OptionablePSTVPlus Therapeutics2017.00 million5.57 millionNot OptionableQNRXQuoin Pharmaceuticals4588,0004.86 millionNot OptionableQNRX, PSTV, PETV, and BSGM HeadlinesRecent News About These CompaniesQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleMay 1 at 8:48 PM | finanznachrichten.deQuoin Pharmaceuticals regains Nasdaq compliance with bid priceMay 1 at 8:48 PM | investing.comQuoin Pharmaceuticals regains Nasdaq complianceApril 30 at 9:56 PM | msn.comQuoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleApril 30 at 7:30 AM | globenewswire.comWhy Quoin Pharmaceuticals, Ltd.’s (QNRX) Stock Is Down 13.50%April 10, 2025 | aaii.comQuoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaignApril 10, 2025 | globenewswire.comQuoin Pharmaceuticals Ltd – ADR trading halted, news pendingApril 9, 2025 | markets.businessinsider.comQuoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirementsApril 6, 2025 | uk.investing.comQuoin announces additional data from Pediatric Netherton Syndrome studyApril 3, 2025 | markets.businessinsider.comQuoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for DosingApril 2, 2025 | reuters.comQuoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric PatientApril 2, 2025 | globenewswire.comQuoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin DiseasesMarch 25, 2025 | globenewswire.comQNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26March 18, 2025 | msn.comQuoin Pharmaceuticals reports Q4 EPS (35c) vs ($2.08) last yearMarch 13, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial ResultsMarch 13, 2025 | globenewswire.comQNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the DiseaseMarch 5, 2025 | msn.comQuoin files U.S., International patent applications for rapamycin formulationsMarch 4, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease IndicationsMarch 4, 2025 | globenewswire.comQuoin Pharmaceuticals’ QRX003 shows potential efficacy in Netherton SyndromeFebruary 28, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome StudyFebruary 27, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNRX, PSTV, PETV, and BSGM Company DescriptionsBioSig Technologies NASDAQ:BSGM$1.22 +0.19 (+18.45%) Closing price 03:59 PM EasternExtended Trading$1.21 -0.01 (-0.82%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioSig Technologies, Inc., together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.PetVivo NASDAQ:PETV$0.60 -0.03 (-4.48%) As of 03:29 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Plus Therapeutics NASDAQ:PSTV$0.65 -0.07 (-9.62%) Closing price 04:00 PM EasternExtended Trading$0.67 +0.02 (+2.45%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Quoin Pharmaceuticals NASDAQ:QNRX$6.85 +0.08 (+1.24%) Closing price 03:50 PM EasternExtended Trading$6.87 +0.01 (+0.18%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
